Obesity causes chronic low-grade inflammation that contributes to systemic metabolic dysfunction associated with obesity-linked disorders that fall under the definition of metabolic syndrome. Adipose tissue is a key endocrine organ as it releases multiple bioactive substances, known as adipose-derived secreted factors or adipokines, that have proinflammatory or anti-inflammatory activities. Dysregulated production or secretion of these adipokines owing to adipose tissue dysfunction can contribute to the pathogenesis of obesity-linked complications. In this emerging context, the gut microbiota-metabolism interactions play an increasingly important role in the understanding and hopefully future treatment of complex metabolic unbalances responsible for insulin resistance and cardiovascular high-risk diseases.

1.
Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85–97.
2.
Shoelson S, Lee J, Goldfine A: Inflammation and insulin resistance. J Clin Invest 2006;116:1793–1801.
3.
Pradhan A, Manson J, Rifai N, Buring J, Ridker P: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–334.
4.
Samaras K, Botelho N, Chisholm D, Lord R: Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity 2010;18:884–889.
5.
Takaoka M, Nagata D, Kihara S, et al: Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009;105:906–911.
6.
Xu H, Barnes GT, Yang Q, et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–1830.
7.
Kosteli A, Sugaru E, Haemmerle G, et al: Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 2010;120:3466–3479.
8.
Khan T, Muise ES, Iyengar P, et al: Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009;29:1575–1591.
9.
Apovian CM, Bigornia S, Mott M, et al: Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008;28:1654–1659.
10.
Pajvani UB, Trujillo ME, Combs TP, et al: Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005;11:797–803.
11.
Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35.
12.
Winer S, Chan Y, Paltser G, et al: Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009;15:921–929.
13.
Friedman J, Halaas J: Leptin and the regulation of body weight in mammals. Nature 1998;395:763–770.
14.
Grunfeld C, Zhao C, Fuller J, et al: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152–2157.
15.
Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
16.
Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789–5795.
17.
Ziccardi P, Nappo F, Giugliano G, et al: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804–809.
18.
Marra M, Campanati A, Testa R, et al: Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007;20:731–736.
19.
Kim HJ, Higashimori T, Park SY, et al: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060–1067.
20.
Pederse B, Febbraio M: Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007;102:814–816.
21.
Li S, Shin H, Ding E, van Dam R: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–188.
22.
Fruebis J, Tsao TS, Javorschi S, et al: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.
23.
Bjursell M, Ahnmark A, Bohlooly-Y M, et al: Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007;56:583–593.
24.
Kim JY, van de Wall E, Laplante M, et al: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621–2637.
25.
Ohashi K, Parker JL, Ouchi N, et al: Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153–6160.
26.
Cani PD, Delzenne NM: Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009;9:737–743.
27.
Cani PD, Bibiloni R, Knauf C, et al: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470–1481.
28.
Cani PD, Amar J, Iglesias MA, et al: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–1772.
29.
Ruan X, Shi H, Xia G, Xiao Y, Dong J, Ming F, Wang S: Encapsulated bifidobacteria reduced bacterial translocation in rats following hemorrhagic shock and resuscitation. Nutrition 2007;23:754–761.
30.
Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R: Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006;55:1484–1490.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.